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The complex relationship between DNA methylation, chromatin modification, and underlying DNA sequence is often
difficult to unravel with existing technologies. Here, we describe a novel technique based on high-throughput sequencing
of bisulfite-treated chromatin immunoprecipitated DNA (BisChIP-seq), which can directly interrogate genetic and epi-
genetic processes that occur in normal and diseased cells. Unlike most previous reports based on correlative techniques,
we found using direct bisulfite sequencing of Polycomb H3K27me3-enriched DNA from normal and prostate cancer cells
that DNAmethylation and H3K27me3-marked histones are not always mutually exclusive, but can co-occur in a genomic
region-dependent manner. Notably, in cancer, the co-dependency of marks is largely redistributed with an increase of the
dual repressive marks at CpG islands and transcription start sites of silent genes. In contrast, there is a loss of DNA
methylation in intergenic H3K27me3-marked regions. Allele-specific methylation status derived from the BisChIP-seq
data clearly showed that both methylated and unmethylated alleles can simultaneously be associated with H3K27me3
histones, highlighting that DNA methylation status in these regions is not dependent on Polycomb chromatin status.
BisChIP-seq is a novel approach that can be widely applied to directly interrogate the genomic relationship between allele-
specific DNA methylation, histone modification, or other important epigenetic regulators.
[Supplemental material is available for this article.]
Epigenetic-based mechanisms play a critical role in gene expres-
sion and cellular differentiation, in both development and disease,
including cancer. The genome-wide distribution of DNA methyl-
ation and chromatinmodifications is now being revealed by large-
scale sequencing studies; however, these techniques only permit
correlative studies between chromatin marks and the underlying
DNA methylation status. To provide further insights into the
complex interactions between different epigenomic states, we
developed a direct genome-wide sequencing approach, to inter-
rogate at base-resolution allele-specific DNA methylation of all
regions marked with a specific histone modification.
Understanding the direct interplay of DNA methylation and
chromatin modification and how these epigenetic marks change
during cellular differentiation and disease is a still a major chal-
lenge in cancer biology. In particular, a key question is what trig-
gers DNA methylation and how the epigenome is remodeled in
cancer cells. CpG island-promoter genes, associated with pluri-
potency of embryonic stem (hES) and progenitor cells, are often
marked with active H3K4 trimethylation (H3K4me3) and re-
pressive H3K27 trimethylation (H3K27me3) histones to form a
bivalent state. Although this pattern was initially reported to be
embryonic stem (ES) cell specific, bivalent domains have also been
found in differentiated somatic cells (Mikkelsen et al. 2007; Mohn
et al. 2008). The CpG-island promoters of bivalent genes in hES
cells constitute a significant fraction of hypermethylated DNA
in cancer cells, leading to the hypothesis that a stem cell signa-
ture and loss of H3K27me3 may trigger aberrant DNA methyla-
tion in malignancy (Ohm et al. 2007; Schlesinger et al. 2007;
Widschwendter et al. 2007). Indeed, DNA methylation and
H3K27me3 occupancy have been reported to be mutually exclusive
in hES cells and cancer cells, using genome-wide approaches (Gal-
Yam et al. 2008; Hahn et al. 2008; Takeshima et al. 2009). However,
we (Coolen et al. 2010) and others (Gal-Yam et al. 2008; Meissner
et al. 2008;Hawkins et al. 2010) have also identified a subset of genes
in cancer that appear to harbor both repressive epigenetic marks.
Genome-wide chromatinmodification studies are commonly
performed using chromatin immunoprecipitation followed by
high-throughput sequencing (ChIP-seq) (Pellegrini and Ferrari
2012). Several methods, however, have been developed to map
global DNA methylation status; most of these are based on one of
three techniques: digestion with methylation-sensitive restriction
enzymes, affinity enrichment of methylated DNA, or chemical
conversion with sodium bisulfite (for review, see Widschwendter
et al. 2007; Laird 2010). The ‘‘gold-standard’’ bisulfite conversion
protocol is the only technique that allows the methylation state of
each cytosine residue in the target sequence to be defined. Whole-
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genome bisulfite sequencing is being applied to organisms with
larger genomes, including mammals (Lister et al. 2009; Laurent
et al. 2010), but the prohibitive cost makes DNA methylation-
based affinity enrichment and reduced representation protocols
followed by sequencing a favorable alternative (Meissner et al.
2008; Gu et al. 2010). The direct relationship between chromatin
modification and DNA methylation at single genes has been
studied by combining ChIP and bisulfite PCR genomic se-
quencing analysis (ChIP-BA) (Matarazzo et al. 2004; Collas 2010;
Angrisano et al. 2011; Li and Tollefsbol 2011). However, due to
the technical challenges of limited DNA generated after ChIP,
epigenome-wide integration studies are still based on ‘‘over-
laying’’ independent chromatin modification and DNA meth-
ylation maps (Gal-Yam et al. 2008; Kondo et al. 2008; Hawkins
et al. 2010).
Here, we undertook a novel approach to directly address
the relationship between Polycomb-bound chromatin and DNA
methylation by performing genome-wide bisulfite sequencing
on H3K27me3-ChIP DNA (Fig. 1A). We resolve the challenges of
performing the bisulfite reaction on small amounts of sonicated
formaldehyde-fixed ChIP DNA, in order to minimize degradation
andmaximize recovery of enoughDNA to enable successful library
generation and sequencing. A custom data analysis pipeline was
also developed that identifies marked genomic regions and calcu-
lates theirmethylation status. Using BisChIP-seq, we directly show
for the first time that H3K27me3-marked histones can bind to
bothmethylated and unmethylated DNA and that this association
is dependent on genomic location, and in cancer the codepen-
dency of marks is largely redistributed. BisChIP-seq is therefore
a novel approach that can be widely applied to study the direct
Figure 1. BisChIP-seq DNA methylation profiles of H3K27me3-enriched DNA from normal PrEC and cancer LNCaP cells. (A) Flowchart of BisChIP-seq
protocol to perform bisulfite treatment and library preparation on H3K27me3-ChIP DNA. (B) Distribution of H3K27me3-enrichment genome-wide
relative to observed over expected and pie charts showing relative distributions across the genome. (C ) Affymetrix Gene 1.0 ST expression values for
H3K27me3-marked and -unmarked genes in PrEC and LNCaP cells. (D) Distribution frequency of CpG methylation levels at H3K27me3-marked regions
that fall into each regional annotation category from low (0%) to high (100%) methylation (0.0–1.0).
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relationship between DNA methylation and other important epi-
genetic regulators.
Results
Optimization of BisChIP-seq protocol
We developed the BisChIP-seq protocol to directly address the re-
lationship between Polycomb-bound chromatin and DNA meth-
ylation. One of the challenges of bisulfite sequencing is the amount
and quality of DNA required for optimal conversion (Clark et al.
1994; Clark et al. 2006). Therefore, before proceeding with bisulfite
treatment of H3K27me3-ChIP DNA, we performed optimizations
using 100 ng of sonicated ChIP input DNA isolated from formal-
dehyde-fixed cells. First, methylated adaptors (Illumina) were li-
gated to the DNA, followed by gel elution size selection (200 6 20
bp) (as required by Illumina sequencing), prior to bisulfite treat-
ment. Two bisulfite methods were compared: the QIAGEN EpiTect
Bisulfite Kit with a 5-h bisulfite treatment and themodifiedmethod
of Clark et al. (2006) with a 4-h bisulfite conversion on very small
amounts of DNA (as expected after gel elution size fractionation). A
methylation-specific headloop suppression PCR (MSH-PCR) (Rand
et al. 2005) was used to assay the yield of positive controls, GSTP1
and EN1. We found that the Clark et al. method with Microcon
YM50 desalting procedure achieved the greatest yield of bisulfite-
converted DNA (Supplemental Fig. 1a,b). Next, we optimized the
steps necessary to enable successful library generation for Illumina
sequencing. Following bisulfite treatment, the efficiency of the li-
brary prep PCRwas tested using 5mL, 10mL, and 22.5mL of adaptor-
modified bisulfite-treated DNA (60 mL) in a 50-mL library PCR re-
action with paired-end primers PE 1.0 and PE 2.0 and PfuTurbo Cx
hotstart DNA polymerase, as per the Illumina protocol and 18 PCR
cycles. We showed that too much bisulfite-treated input DNA
(22.5 mL) had an inhibitory effect on the library preparation yield
(Supplemental Fig. 1c). The number of PCR cycles was also opti-
mized to give sufficient yield in the library preparation without
compromising the complexity of the library by overamplification.
We tested 10, 12, 14, and 18 PCR cycles, and 14 cycles gives ad-
equate yield for high-throughput sequencing (Supplemental
Fig. 1d).
Chromatin immunoprecipitation with H3K27me3 antibody
was performed on a prostate cancer cell line (LNCaP) and normal
prostate epithelial cells (PrEC) and validation of H3K27me3 en-
richment was confirmed by qPCR of known candidate genes
(Supplemental Fig. 2; Coolen et al. 2007). For the BisChIP-seq
protocol (Fig. 1A), the H3K27me3 ChIP DNA (75–100 ng, re-
spectively) was resonicated and checked on an Agilent Technolo-
gies 2100 Bioanalyser to ensure the maximum yield of DNA in the
150-bp size range, followed by ligation of methylated paired-end
adaptors (Illumina) and size selection by gel elution near 200 bp.
Bisulfite treatment was performed for 4 h on the gel-eluted
H3K27me3 ChIP DNA as per the Clark et al. (2006) protocol with
optimizations (described in Methods), and sequencing libraries
were generated (using optimized conditions, described above). A
sample (1 mL) from the library preparation was checked on an
Agilent Technologies 2100 Bioanalyser (Supplemental Fig. 1e) to
confirm successful library generation after bisulfite treatment and
with sufficient yield for Illumina sequencing, before cluster gen-
eration and Illumina GAIIx sequencing (75-bp paired-end, three
lanes of PrEC and four lanes of LNCaP) (Supplemental Table 1).
Using the methodology described above, we show that we can
perform bisulfite treatment on ChIP DNA and successfully gener-
ate a library for sequencing. The amount of DNA obtained from
any ChIP will clearly depend on the type of antibody used and the
abundance of the mark in each cell type, and here we show that
<100 ng of DNA is sufficient for Illumina bisulfite sequencing.
Analysis of BisChIP-seq data
Sequences from the bisulfite-treated H3K27me3-ChIP DNA were
mapped using a custom pipeline for the alignment of paired-end
bisulfite ChIP reads, adapted from the procedure described in Lister
et al. (2009) (see Methods). A total of 38,403,614 and 70,682,755
reads were obtained for PrEC and LNCaP, respectively, with a bi-
sulfite conversion rate of 99.7% for PrEC and 99.8% for LNCaP
(Supplemental Table 1). We used ChromaBlocks, a procedure for
detecting large regions of lowenrichment, as expected forH3K27me3
(Hawkins et al. 2010). In total, 53,749 and 52,677 regions were
enriched (FDR < 0.001), covering 148.6 Mb and 139.9 Mb in PrEC
and LNCaP (Table 1), respectively, comparable to the results of
Hawkins et al. (2010). H3K27me3-marked DNA was enriched
preferentially at transcription start sites (TSSs) and CpG islands in
both cell types, while exons, introns, and intergenic regions were
not significantly enriched in these regions (Fig. 1B; Table 1). In
total, 5029 and 4639 TSSs were marked by H3K27me3 in PrEC and
LNCaP, respectively, and expression of these genes was at basal
levels, correlating with the role of H3K27me3 in gene repression
(Fig. 1C; Table 1).
The proportion of cytosine base calls that are not bisulfite-
converted at CpG dinucleotides is used to determine DNA meth-
ylation levels. Using a minimum of 10 reads, the methylation
status on the plus and minus strand of individual CpG sites was
shown to be highly concordant (Supplemental Fig. 3) (r = 0.94
and 0.91 in PrEC and LNCaP, respectively). Therefore, the two
strands were pooled, allowing us to interrogate 2,482,996 and
2,552,762 CpG sites in PrEC and LNCaP, respectively (Table 2); <1%
of H3K27me3-enriched regions had insufficient coverage to deter-
mine methylation levels. Methylation levels assessed from the
H3K27me3-enriched regions are also highly concordant (r = 0.932,
PrEC; r = 0.925, LNCaP) with lower-resolution Infinium 450K array
methylation data obtained from native LNCaP and PrEC DNA
(Supplemental Fig. 4a) (see Methods). Example comparisons of
BisChIP-seq methylation and clonal bisulfite sequencing from
native DNA show that bisulfite-based DNAmethylation results are
not affected by prior cross-linking (Supplemental Fig. 4b).
Bimodal DNA methylation profiles of H3K27me3-enriched
regions are redistributed in cancer
In normal prostate PrEC cells, the H3K27me3-enriched regions,
which overlap with the TSSs or CpG islands, show bimodal DNA
Table 1. ChromaBlocks analysis of BisChIP-Seq data
PrEC H3K27me3.Bis-Chip LNCaP H3K27me3.Bis-Chip
Number of
regions
Number of
base pairs
covered
Number of
regions
Number of
base pairs
covered
All regions 53,749 148,619,149 52,677 139,971,277
TSS 5029 24,414,429 4639 20,470,339
CpG islands 10,556 47,446,856 8408 36,977,208
Exons 17,762 63,179,562 13,209 45,696,509
Introns 28,394 86,217,694 24,752 70,352,052
Intergenic 30,106 88,335,206 31,918 89,441,018
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methylation profiles; that is, the regions are predominantly asso-
ciated with either unmethylated or methylated DNA (Fig. 1D). In
contrast, exons, introns, and intergenic H3K27me3-enriched re-
gions are primarily associated with methylated DNA (Fig. 1D).
Surprisingly in the prostate cancer cells, H3K27me3-enriched re-
gions are associated with different DNA methylation profiles to
normal prostate cells, and this redistribution of dual repressive
marks in cancer is dependent on genomic location and density of
methylation. Exons, introns, and intergenic H3K27me3-enriched
regions are comparatively depleted in highly methylated DNA. In
contrast, H3K27me3-enriched TSSs and CpG islands show an in-
creased association with medium to highly methylated DNA and
a reduced binding to lowly methylated DNA (Fig. 1D; Table 2). For
example, 3330 (;71.7%) of the LNCaP TSS regions show medium
or high levels of DNAmethylation, whereas only 2866 TSS regions
(57.0%) in normal cells were marked by both H3K27me3 and
medium or high levels of DNAmethylation (x2 test, p < 13 1015).
One example region that shows a cancer-associated redistribution
ofmarks is the RCSD1CpG island promoter, where similar levels of
H3K27me3 enrichment are observed in normal and cancer cells,
and yet the sameRCSD1CpG island is unmethylated in the normal
cell and hypermethylated in the cancer cell (Fig. 2A). This pattern
of dual repressive marks is observed in a subset of normally silent
CpG island promoters, where the gain of extensive DNA methyl-
ation in cancer is not associated with a loss of H3K27me3 (Sup-
plemental Fig. 5a–d). These data directly show that DNA methyl-
ation and H3K27me3 are not mutually exclusive, but can co-occur
at TSSs. Interestingly, all of the H3K27me3-associated genes were
repressed regardless of the level of DNA methylation (Supple-
mental Fig. 6).
Allele-specific DNA methylation at H3K27me3-marked
regions
Using BisChIP-seq, we could directly interrogate allele-specific
DNA methylation at H3K27me3-marked regions that contain
heterozygous single nucleotide polymorphisms (SNPs). Approxi-
mately 106,887 SNPs and 215,628 SNPS had sufficient coverage in
the H3K27-ChIP bisulfite sequencing data (at least 20 reads) from
PrEC and LNCaP, respectively, to make genotype calls, resulting in
6472 and 13,034 clear heterozygous SNPs (see Methods). Of these,
762 and 1195 exhibited strong evidence of allele-specific differ-
ential methylation (difference-in-proportions test, FDR < 0.05)
in H3K27me3-enriched regions; that is, both methylated and
unmethylated alleles were equally bound by the Polycomb mark.
For example, SNP rs637481 shows either high or low levels of
methylation on the A and G allele, respectively, in PrEC (Fig. 2B);
more allele-specific differentialmethylation examplesofH3K27me3-
enriched regions in both PrEC and LNCaP
are shown in Supplemental Figure 7a and
b. These data directly show that in normal
cells, H3K27me3 marks many regions in-
dependent of DNA methylation and the
underlying sequence.
Discussion
Here, we report a novel method, which
combines bisulfite-conversion method-
ology with chromatin immunoprecipita-
tion and deep sequencing, that allows
a direct genome-wide interrogation of
two epigenetic marks for the first time on the same DNAmolecule.
Previous methods by themselves have only allowed correlative
studies of the epigenome to be assessed that do not take into account
potential allele-specific differences. We show that H3K27me3 poly-
comb-bound histones are not always mutually exclusive with DNA
methylation but can co-occur in a genomic region-dependent man-
ner and this co-occurrence is remodeled in cancer.
It is intriguing that in the normal somatic epithelial cell, we
find a discrete bimodal distribution ofH3K27me3, with either fully
methylated or unmethylated DNA at TSS and CpG islands, whereas
in exonic, intronic, or intergenic regions, H3K27me3 primarily as-
sociates only with methylated DNA. By overlaying chromatin-
modification profiles and DNA methylomes in hESCs and primary
fibroblasts, Hawkins et al. (2010) also found that nearly one-third of
the genome differs in chromatin structure on differentiation, with
dramatic redistributions of repressive H3K27me3 marks. However,
in contrast to our findings, they found that H3K27me3 is primarily
associatedwith unmethylatedDNAat promoters in IMR90 cells, but
outside of promoters, H3K27me3 was associated with DNA meth-
ylation. These results may reflect different cell type–specific re-
lationships between DNA methylation and histone modifications,
or may highlight the fact that direct bisulfite methylation se-
quencing of ChIPDNA allows amore sensitive analysis of a subset
of these two epigenetic marks.
In cancer, we found an extensive alteration of the distribution
H3K27me3-modified histones and the relationship with DNA
methylation status. Notably, there was an increase in regions with
the dual repressive marks at TSSs and CpG islands and a loss or
decrease in the extent of DNAmethylation inH3K27me3-enriched
intronic and exonic sequences. Interestingly, there was also a pro-
nounced shift in preference for H3K27me3 to bind unmethylated
DNA in intergenic regions. It is possible that the gross alteration of
patterns that are observed here may simply reflect that changes in
DNA hypomethylation and hypermethylation are independent
of H3K27me3 occupancy in cancer; that is, H3K27me3-mediated
silencing is mechanistically distinct from DNA methylation-
associated silencing (Kondo et al. 2008). Indeed, we found that all
H3K27me3-marked regions were repressed independent of the
level of DNAmethylation, and therefore the relationship between
H3K27me3 and DNA methylation levels may be more complex
thanpreviously proposed (Suzuki andBird2008;Cedar andBergman
2009), in both normal differentiation and malignancy.
One of the other primary advantages of BisChIP-seq is the use
of single-molecule bisulfite sequencing to directly interrogate al-
lele-specific methylation of ChIP DNA. Interestingly, using this
technique, we demonstrate thatH3K27me3-modifiedhistones can
bind directly to both methylated and unmethylated alleles in the
same cell, further supporting the concept that H3K27me3 and
Table 2. DNA methylation levels of H3K27me3-enriched regions
PrEC
NDa
PrECb
Low
PrECb
Medium
PrECb
High
LNCaP
NDa
LNCaPb
Low
LNCaPb
Medium
LNCaPb
High
All regions 80 (0.15%) 3665 7610 42,394 26 (0.05%) 14,549 21,209 16,893
TSS 1 (0.02%) 2162 1318 1548 0 (0.00%) 1309 2473 857
CpG islands 0 (0.00%) 3243 2650 4663 0 (0.00%) 1713 3939 2756
Exons 3 (0.02%) 2468 2358 12,933 1 (0.01%) 2270 5549 5389
Introns 21 (0.07%) 2521 3381 22,471 8 (0.03%) 5251 9467 10,026
Intergenic 60 (0.20%) 2989 5430 21,627 18 (0.06%) 10,376 14,030 7494
(Low) 0%–20% methylation. (Medium) 20%–60% methylation. (High) 60%–100% methylation.
aNot determined, that is, the number of H3K27me3 regions with less than >103 coverage.
bNumber of H3K27me3 regions with an average of all CpGs with >103 coverage.
Bisulfite seq of chromatin immunoprecipitated DNA
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Figure 2. BisChIP-seq examples showing differential methylation and allele-specific methylation in H3K27me3-enriched ChIP DNA. (A) UCSCGenome
Browser screen shot of BisChIP-seq data showing the RCSD1 TSS and CpG island, where H3K27me3-modified histones are enriched in both PrEC and
LNCaP. (Purple shading) In PrEC cells the CpG island is unmethylated, whereas in LNCaP cells the island becomes extensively DNA methylated without
losing the H3K27me3mark. Individual bisulfitemethylation sequencing reads are shownwith CpG sites (black circles) in yellow shading for eachmolecule.
(Red circles) CpGDNAmethylation. (B) Example of allele-specific methylation in PrEC cells at rs637481 on chromosome 1. UCSCGenome Browser screen
shot of BisChIP-seq data indicates regions of significant H3K27me3-enrichment called by ChromaBlocks. (Purple line) Position of the A/G SNP at rs637481.
Individual bisulfitemolecule sequencing reads are shownwith all CpG sites in the sequence (black circles) in yellow shading for eachmolecule. (Red circles)
BisChIP-seq readout of CpG DNA methylation. The allele-specific methylation ratio is indicated by bar graphs.
 Cold Spring Harbor Laboratory Press on June 12, 2020 - Published by genome.cshlp.orgDownloaded from 
DNA methylation are not mutually exclusive and can either work
independently and/or cooperatively to enforce gene silencing. The
concept of what establishes allele-specific methylation in a nor-
mal cell, however, is still an open question, but clearly in some
genomic contexts appears to be independent of the presence of
H3K27me3-modified chromatin.
In summary, we demonstrate that BisChIP-seq is a cost-effective
novel approach that may be applied to directly interrogate the
interactions between DNA methylation and other histone modi-
fications, as well as other important epigenetic regulators, such
as transcription factors that can be enriched by genome-wide im-
munoprecipitation. Specifically, using BisChip-seq, we showed that
both methylated and unmethylated alleles can be associated with
H3K27me3-enrichedDNA and that in cancer the relationship of the
bimodal repressivemarks is altered in a regional-dependentmanner.
Our results highlight the importance of studying allele-specificDNA
methylation and chromatinmarks directly, because thesemay have
different patterns in different sequence and cellular contexts.
Methods
Cell culture
LNCaP prostate cancer cells were cultured as described previously
(Song et al. 2002). Normal prostate epithelial cells (PrECs) (Cam-
brex Bio Science cat. no. CC-2555) were cultured according to the
manufacturer’s instructions in Prostate Epithelial Growth Media
(PrEGM) (Cambrex Bio Science cat. no. CC-3166).
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) assays were performed
according to the manufacturer’s instructions (Millipore). Briefly,
;13 106 cells, in a 10-cmdish,were fixed by adding formaldehyde
to a final concentration of 1% and incubating for 10 min at 37°C.
The cells were washed twice with ice-cold PBS containing protease
inhibitors (1 mM phenylmethylsulfonyl fluoride [PMSF], 1 mg/mL
aprotinin, and 1 mg/mL pepstatin A), harvested, and treated with
SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris at pH 8.1) for
10 min on ice. The resulting lysates were sonicated to shear the
DNA to fragment lengths of 200–500 bp. The complexes were
immunoprecipitated with antibodies specific for tri-methyl-histone
H3(lys27) (Millipore #07-449/lot number #DAM 1514011; this anti-
body lot was previously [Egelhofer et al. 2011] shown to be 100%
specific with no cross-reactivity using a panel of modified peptides
on a dot blot assay [http://compbio.med.harvard.edu/antibodies/
antibodies/56]). Ten microliters of antibody was used for each im-
munoprecipitation according to the manufacturer’s instructions. A
no-antibody control was included for each ChIP assay, and this
showed a lack of non-specific precipitation by quantitative Real-Time
PCR analysis. Input sampleswere processed inparallel. The antibody/
protein complexes were collected by Protein A/G PLUS agarose beads
(Santa Cruz sc-2003) and washed several times following the manu-
facturer’s instructions. The immune complexes were eluted with 1%
SDS and 0.1 M NaHCO3; samples were treated with proteinase K for
1 h; and DNA was purified by phenol:chloroform extraction and
ethanol precipitation and resuspended in 30 mL of H2O. qPCR vali-
dation of H3K27me3 enrichment using known candidate genes was
performed (ChIP primers in Supplemental Table 2).
Preparation of ChIP DNA for bisulfite treatment
and Illumina Genome Analyzer
H3K27me3-ChIPDNAwas pooled from three to five ChIP assays to
obtain 100 ng of DNA for adaptor ligation and gel-size elution,
followed by bisulfite treatment. The ChIP DNA was concentrated
by ethanol precipitation to give a final yield of 100 ng of ChIPDNA
in 40 mL of water. The ChIP DNA was further sonicated using
a Bioruptor (High, 30 sec on and 30 sec off for 25min) to ensure the
maximum yield of DNA in the size range of 150–200 bp and
checked on a bioanalyzer. End repair and addition of A bases to the
39 end of the DNA fragments were performed according to the
‘‘Preparing Samples for ChIP Sequencing of DNA’’ (Illumina Part
#11257047 Rev.A). Methylated paired-end adaptors undiluted
(Illumina Part #1005560) were then ligated onto the ChIP DNA
using 1mL of undilutedmethylated adaptor oligomix, 4mL ofDNA
ligase (Illumina Part #1000522), in a total reaction volume of 10mL
for 15 min at room temperature. The reactions were cleaned up
using the MinElute PCR Purification Kit (QIAGEN Part #28004)
and eluted in 10 mL of EB buffer following the manufacturer’s in-
structions. Size selection of the library was performed according to
the Illumina protocol for ‘‘Preparing Samples for ChIP Sequencing
of DNA’’ (Illumina Part #11257047 Rev.A). Two microliters of
loading buffer was added to 10 mL of DNA, and the entire sample
was loaded onto a single lane of the gel. A gel slice in the range of
200 6 20 bp was excised and eluted using the QIAGEN Gel Ex-
tractionKit (QIAGENPart #28704) and eluted in 40mL of EB buffer.
Bisulfite treatment of ChIP DNA
Bisulfite conversion was performed with minor modifications of
theClark et al. (2006) protocol. The bisulfite reactionswere done in
duplicate. One microliter of tRNA (10 mg/mL) was added to the 20
mL of DNA in a final volume of 21 mL. Then 2.33 mL of 3 M NaOH
was added to each 21-mL DNA sample and incubated for 15 min at
37°C and 2 min at 90°C, placed on ice, and then centrifuged
briefly. Next, 208 mL of saturated sodium metabisulfite (pH 5.0)
(7.6 g of Na2S2O5 with 464 mL of 10 M NaOH made up to 15 mL
with water) and 12 mL of 10 mM quinol were added, vortexed,
briefly centrifuged, and incubated for 4 h at 55°C in a PCR ma-
chine. The bisulfite reaction was cleaned up using the Microcon
YM50 device (Millipore). The duplicate bisulfite reactions were
combined in a new tube, and 1 mL of tRNA (10 mg/mL) was added
before transferring to a Microcon YM50 column. The column was
spun at 14,000g for 25 min at room temperature. The filtrate was
discarded, and 350 mL of H2O was added to the column and spun
for a further 12 min at room temperature. This wash step was re-
peated. After discarding the filtrate, 350 mL of 0.1MNaOH (freshly
prepared) was added to the column for the desulfonation step and
again spun at 14,000g for 10min at room temperature; a final wash
of 350 mL of H2O was followed by a 12-min spin at room temper-
ature at 14,000g. The columnwas placed in a fresh tube, and 60 mL
of H2Owas added and gently pipetted up and down and allowed to
stand for 5 min before being inverted and spun at 1000g for 3 min
to transfer the bisulfite-treated DNA into the microfuge tube. The
bisulfite-treated DNA was stored at 20°C. The QIAGEN EpiTect
Bisulfite Kit (cat. no. 59104) was performed according to the manu-
facturer’s instructions for bisulfite treatment of ‘‘low concentrations
of DNA.’’ Quantitation of bisulfite conversion and DNA yield was
compared using Methylation Specific Headloop PCR (MSH-PCR).
MSH-PCR primers, probes, and conditions for EN1 and GSTP1 are as
described previously (Rand et al. 2005).
Library preparation of bisulfite-treated ChIP DNA
Five microliters of bisulfite-treated DNA (from above) was used in
the PCR amplification step for library preparation. Triplicate 50-mL
PCR reactions were set up as follows: 5 mL of DNA, 1.25 mL of
dNTPs (10 mM) (Illumina #1000564), 1 mL of PCR primer PE 1.0
(Illumina Part #1001783), and 1 mL of PCR primer PE 2.0 (Illumina
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Part #1001784), in 13 PfuTurbo Cx reaction buffer (Stratagene
#6000410) and 1 mL of PfuTurbo Cx Hotstart DNA polymerase (2.5
U/mL; Stratagene #600410). The PCR reaction was performed for
5 min at 95°C, 30 sec at 98°C, followed by 14 cycles of 10 sec at
98°C, 30 sec at 65°C, 30 sec at 72°C, for 14 cycles, then 5 min at
72°C; and hold at 4°C. The reactions were cleaned up following
the instructions of the MinElute PCR Purification Kit, eluting
each reaction in 15 mL of EB buffer, and pooling the triplicate
reactions to give a final volume of 45 mL. One microliter was
checked on an Agilent Technologies 2100 Bioanalyzer. Twenty
microliters was sent to Illumina for cluster generation and GAIIx
sequencing.
Alignment of bisulfite-treated sequencing reads
A custom pipeline was written for the alignment of paired-end
bisulfite ChIP reads, adapted from the procedure described in Lister
et al. (2009) (available from http://github.com/astatham/Bisulfite-
seq-pipeline). Briefly, methylation information was removed from
reads (C’s in read 1 replaced with T’s; G’s in read 2 replaced with
A’s), and reads were then mapped separately to both strands of the
bisulfite-converted hg18 genome using Bowtie with the following
parameters (-solexa1.3-quals -nomaqround -n 3 -l 24 -e 300 -y -k
10). Reads from the two strands were collated and ranked by the
number ofmismatches against the reference; only readswith fewer
than six mismatches that were three mismatches closer to the
reference than the next best hit were retained as unique (for
mapping statistics, see Supplemental Table 1). Since the median
fragment size for our paired-end libraries (119-bp PrEC and 114-bp
LNCaP) was less than the read length (150 bp), the majority of the
fragment sequences overlapped in the middle; to avoid doubling
up on base calls, these fragments were merged into single contig
reads, with disagreements between base calls decided by higher-
quality scores; ties were decided randomly. The number of meth-
ylated (C) and unmethylated (T) base calls at each CpG site within
the genome was then extracted and imported into R for down-
stream analysis.
Detection of H3K27me3-enriched regions
Regions of enrichmentwere determined using an adaptationof the
ChromaBlocks algorithm (Hawkins et al. 2010) for identifying
both strong peaks and regions of broad enrichment, as implemented
in the Repitools package (Statham et al. 2010).
Gene expression array data
Affymetrix Gene 1.0 ST array data for LNCaP and PrEC cells is
available at NCBI’s Gene Expression Omnibus (GEO) under ac-
cession number GSE19726. Robust multi-chip analysis (RMA) was
used to summarize probe-level data, and probe GC content effects
were removed by subtracting the mode of RMA expression values
in bins of average probe GC content.
Infinium HumanMethylation450 BeadChips
Genomic DNA was isolated from PrEC and LNCaP cells using the
QIAamp Mini kit (QIAGEN) following the manufacturer’s in-
structions. Hybridizations to Infinium HumanMethylation450
BeadChips (Illumina) were performed in triplicate as a service
by the Australian Genome Research Facility. The ‘‘minfi’’ Bio-
conductor package was used to process raw data into methylation
‘‘beta’’ values using the ‘‘preprocessIllumina’’ functionwith default
options for background correction and normalization.
Detection of allele-specific methylation (ASM)
To detect allele-specific methylation (ASM), all known single-nu-
cleotide variant positions in hg18 were extracted from dbSNP 130
using the UCSC Table Browser. The number of A, C, G, and T base
calls at each SNP positionwas extracted fromaligned bisulfite reads
using samtools (Li et al. 2009); SNPs with <203 coverage were
discarded. The remaining SNP positions were deemed potentially
heterozygous when the proportion of base calls containing the
reference was not significantly different from 0.5 (p > 0.05)
(prop.test in R). Full-length bisulfite reads overlapping hetero-
zygous SNPs were extracted, and the change in proportion of
(surrounding) methylated CpGs was tested using the difference-
in-proportions test (FDR < 0.05). SNPs that overlapped a CpG site
were excluded from this analysis.
Data access
The 450k array andBisK27ChIP-seq data from this study have been
submitted to NCBI’s Gene Expression Omnibus (GEO) (http://
www.ncbi.nlm.nih.gov/geo) under accession nos. GSE34340 and
GSE30558, respectively. The SuperSeries accession that connects
data is GSE34403.
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